中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2014年
5期
489-492
,共4页
潘力健%潘娟娟%刘磊%史益军%龚辉
潘力健%潘娟娟%劉磊%史益軍%龔輝
반력건%반연연%류뢰%사익군%공휘
冠心病%骨形态发生蛋白4%瑞舒伐他汀%氧化应激%内皮功能
冠心病%骨形態髮生蛋白4%瑞舒伐他汀%氧化應激%內皮功能
관심병%골형태발생단백4%서서벌타정%양화응격%내피공능
Coronary heart disease%Bone morphogenetic protein-4%Rosuvastatin%Oxidative stress%Endothelial function
目的 探讨冠心病(CHD)患者血浆骨形态发生蛋白4(BMP-4)水平的变化及瑞舒伐他汀治疗对BMP-4水平的影响.方法 CHD患者52例,同期选择我院健康体检者35名作为正常对照组(NC组).采用ELISA法检测血浆BMP-4浓度,分析血浆BMP-4水平与血脂、血流介导的血管内皮舒张功能(FMD)、一氧化氮(NO)、环氧化酶2(COX-2)、丙二醛(MDA)、超氧化物歧化酶(SOD)等的关系.同时观察瑞舒伐他汀干预前后CHD患者血浆BMP-4水平的变化.结果 CHD组血浆BMP-4水平均明显高于NC组[(7.53±1.20) μg/L与(3.81±0.79) μg/L,t =3.541,P=0.006].CHD组经瑞舒伐他汀治疗后血浆BMP4水平明显降低[(7.53±1.20) μg/L与(5.40±0.98) μg/L,t=1.436,P=0.001].CHD患者血浆BMP-4水平与COX-2、MDA、低密度脂蛋白胆固醇、总胆固醇正相关(r=0.395、0.350、0.274、0.288,P＜0.01或P＜0.05),与NO、高密度脂蛋白胆固醇、SOD、FMD负相关(-0.291、-0.253、-0.476、-0.320,P＜0.01或P＜0.05).COX-2、SOD和FMD是影响CHD患者血浆BMP-4水平的独立相关因素.结论 冠心病患者存在氧化应激损伤和血管内皮功能障碍.瑞舒伐他汀可降低BMP-4水平,减轻血管内皮氧化应激损伤,改善冠心病患者的血管内皮功能.
目的 探討冠心病(CHD)患者血漿骨形態髮生蛋白4(BMP-4)水平的變化及瑞舒伐他汀治療對BMP-4水平的影響.方法 CHD患者52例,同期選擇我院健康體檢者35名作為正常對照組(NC組).採用ELISA法檢測血漿BMP-4濃度,分析血漿BMP-4水平與血脂、血流介導的血管內皮舒張功能(FMD)、一氧化氮(NO)、環氧化酶2(COX-2)、丙二醛(MDA)、超氧化物歧化酶(SOD)等的關繫.同時觀察瑞舒伐他汀榦預前後CHD患者血漿BMP-4水平的變化.結果 CHD組血漿BMP-4水平均明顯高于NC組[(7.53±1.20) μg/L與(3.81±0.79) μg/L,t =3.541,P=0.006].CHD組經瑞舒伐他汀治療後血漿BMP4水平明顯降低[(7.53±1.20) μg/L與(5.40±0.98) μg/L,t=1.436,P=0.001].CHD患者血漿BMP-4水平與COX-2、MDA、低密度脂蛋白膽固醇、總膽固醇正相關(r=0.395、0.350、0.274、0.288,P＜0.01或P＜0.05),與NO、高密度脂蛋白膽固醇、SOD、FMD負相關(-0.291、-0.253、-0.476、-0.320,P＜0.01或P＜0.05).COX-2、SOD和FMD是影響CHD患者血漿BMP-4水平的獨立相關因素.結論 冠心病患者存在氧化應激損傷和血管內皮功能障礙.瑞舒伐他汀可降低BMP-4水平,減輕血管內皮氧化應激損傷,改善冠心病患者的血管內皮功能.
목적 탐토관심병(CHD)환자혈장골형태발생단백4(BMP-4)수평적변화급서서벌타정치료대BMP-4수평적영향.방법 CHD환자52례,동기선택아원건강체검자35명작위정상대조조(NC조).채용ELISA법검측혈장BMP-4농도,분석혈장BMP-4수평여혈지、혈류개도적혈관내피서장공능(FMD)、일양화담(NO)、배양화매2(COX-2)、병이철(MDA)、초양화물기화매(SOD)등적관계.동시관찰서서벌타정간예전후CHD환자혈장BMP-4수평적변화.결과 CHD조혈장BMP-4수평균명현고우NC조[(7.53±1.20) μg/L여(3.81±0.79) μg/L,t =3.541,P=0.006].CHD조경서서벌타정치료후혈장BMP4수평명현강저[(7.53±1.20) μg/L여(5.40±0.98) μg/L,t=1.436,P=0.001].CHD환자혈장BMP-4수평여COX-2、MDA、저밀도지단백담고순、총담고순정상관(r=0.395、0.350、0.274、0.288,P＜0.01혹P＜0.05),여NO、고밀도지단백담고순、SOD、FMD부상관(-0.291、-0.253、-0.476、-0.320,P＜0.01혹P＜0.05).COX-2、SOD화FMD시영향CHD환자혈장BMP-4수평적독립상관인소.결론 관심병환자존재양화응격손상화혈관내피공능장애.서서벌타정가강저BMP-4수평,감경혈관내피양화응격손상,개선관심병환자적혈관내피공능.
Objective To investigate the changes of plasma bone morphogenetic protein-4 (BMP-4) levels in patients with coronary heart disease (CHD) and rosuvastatin intervention effect on BMP-4 level.Methods Fifty-two patients with CHD and 35 health people were enrolled in this study as CHD group and control group.ELISA method was used to detect the concentration of plasma BMP-4.Analyzed the relationship between plasma BMP-4 and blood lipids,flow-mediated dilation (FMD),nitric oxide (NO),cyclooxygenase-2 (COX-2),malondialdehyde (MDA) and superoxide dismutase (SOD).And observed the changing of plasma BMP-4 before and after rosuvastatin intervention.Results Plasma BMP-4 level in CHD patients was (7.53 ± 1.20) μg/L,higher than that of control group ((3.81 ± 0.79) μ g/L,t =3.541,P =0.006).After rosuvastatin treatment,plasma BMP-4 level in CHD patient was decreased from (7.53 ± 1.20) μg/L to (5.40± 0.98) μg/L (t =1.436,P =0.001).Plasma BMP-4 level was positively correlated with COX-2,MDA,low-density lipoprotein cholesterol,total cholesterol (r =0.395,0.350,0.274,0.288 respectively,P ＜ 0.01 or P ＜0.05).But,it was negatively correlated with NO,high-density lipoprotein cholesterol,SOD,FMD (r =-0.291,-0.253,-0.476,-0.320 respectively,P ＜0.01 or P ＜0.05).COX-2,SOD and FMD were independent risk factors of plasma BMP-4 in patients with CHD.Conclusion Oxidative stress and endothelial dysfunction are in patients with CHD.Rosuvastatin treatment can remarkably reduce plasma BMP-4 level,alleviate vascular endothelium injury induced by oxidative stress and improve endothelial function in patients with CHD.
